20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
International Linked Clinical Trials strategic funding for Parkinson’s now worth US$6.75 million
LONDON (21 September, 2020) The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The John Black Charitable Foundation (JBCF), to the International Linked Clinical Trials (iLCT) programme. Together, these three partners have pledged a total…
The John Black Charitable Foundation joins Cure Parkinson’s as Strategic funding partner
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The John Black Charitable Foundation (JBCF), to the International Linked Clinical Trials (iLCT) programme.
Drug shows signs of efficacy in early stage Parkinson’s
A protein called alpha-synuclein builds up in the brains of people with Parkinson’s. This accumulation is believed to play a role in the progressive nature of Parkinson’s.
The PD-STAT/Simvastatin study results
Why is this important? In 2012, an international committee of Parkinson’s experts brought together by Cure Parkinson’s prioritised simvastatin for clinical evaluation in Parkinson’s. The International Linked Clinical Trials (iLCT) committee believed that there was considerable supporting evidence indicating that this widely used medication may…
Dexamethasone for COVID – and perhaps Parkinson’s?
Recent studies screening medical record databases suggest anti-inflammatory drugs like dexamethasone may reduce the risk of developing Parkinson’s.